FDA Approves Polatuzumab Vedotin Plus R-CHP for Previously Untreated DLBCL

The FDA has approved polatuzumab vedotin-piiq plus rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for certain patients with treatment-naive diffuse large B-cell lymphoma.

Related Keywords

Roche Polivy ,Oncologic Drugs Advisory Committee ,International Prognostic Index ,Youtube ,Meeting Of The Oncologic Drugs Advisory Committee ,Drugs Advisory Committee ,Pacific Lymphoma Conference ,Polatuzumab Vedotin Piiq ,Diffuse Largeb Cell Lymphoma ,Dlbcl ,